Innovativeradiopharmaceuticalfor diagnosisof heart disease
Syn2bio
Syn2bio
Who are we?
Syn2bio SA was established pursuant to the decision of the management board of Synektik SA of 27 March 2025 on the planned division of the company. An organized part of the enterprise of Synektik SA will be spun off into a new entity, Syn2bio, including:
- The cardiotracer project – an innovative radiopharmaceutical for diagnosis of heart disease,
- The Centre for Research on New Compounds – a unit engaged in the search for innovative new pharmaceutical compounds and their further study, registration, and market launch as a medicinal product.
Cardiotracer
Our flagship project
The SYN2 cardiotracer is an innovative radiopharmaceutical designed for testing myocardial perfusion and diagnosis of coronary artery disease. It enables:
- Detection of myocardial perfusion disorders,
- Evaluation of the patient’s condition after a heart attack, or suffering from ischemic heart disease,
- Assessment of the severity of atherosclerotic lesions in the coronary arteries.
In the company’s view, this project has global commercial potential. The cardiotracer is covered by patent protection in key markets, particularly in Europe and Japan, and is in the process of obtaining patent protection in the United States.
Synektik has successfully completed phase one and phase two of clinical trials. The project is currently in advanced phase-three clinical trials. Syn2bio will take over the further research and commercialization of this radiopharmaceutical.
Company authorities
Syn2bio SA Management Board
Cezary Kozanecki
CEO
Anna Szymańska
Management Board Member
Syn2bio SA Supervisory Board
Mariusz Książek
Chair of the Supervisory Board
Wiesław Łatała
Vice-Chair of the Supervisory Board
Sawa Zarębińska
Supervisory Board Secretary
Piotr Chudzik
Supervisory Board Member
Robert Pikus
Supervisory Board Member
Cezary Kozanecki
CEO
Cezary Kozanecki has been affiliated with the medical sector since 1990, where for many years he was responsible for strategic areas of sales and organizational management. In 2001 he founded Synektik, the leading Polish producer of radiopharmaceuticals and a supplier of advanced solutions for medicine, including innovative medical devices and IT solutions. Kozanecki has served as CEO of Synektik SA and the Synektik Group continually since the beginning of the company’s operations.
Kozanecki was also one of the founders and first shareholders of one of the biggest private medical networks in Poland. For many years he also performed key roles in the management board and supervisory board of the POLMED National Chamber of Commerce for Medical Devices.
Cezary Kozanecki completed studies in veterinary medicine in 1986 at the Warsaw University of Life Sciences (SGGW). In the 1980s he conducted scientific research on invasive diseases. He is also the creator of patented inventions in the field of medicine.
Anna Szymańska
Management Board Member
Anna Szymańska, who also serves as director of the office of the Synektik SA management board, has extensive, long-term experience in the administration, functioning and organization of the work of management boards, support for sessions of corporate authorities, and building the companies’ professional image in external contacts.
Her experience also includes ensuring the smooth operation of the office, including HR management, maintaining correspondence with state authorities (KRS, KDPW, GPW, UKNF), ensuring the proper circulation of information, and support for the management board in its day-to-day activities and implementation of internal policies and procedures.
Anna Szymańska holds a university degree in the humanities.
Mariusz Książek
Chair of the Supervisory Board
Wiesław Łatała
Vice-Chair of the Supervisory Board
Sawa Zarębińska
Supervisory Board Secretary
Piotr Chudzik
Supervisory Board Member
Robert Pikus
Supervisory Board Member
Strategy
Syn2bio strategy
Syn2bio’s strategy is focused on building value for shareholders through effective commercialization of the cardiotracer SYN2 – an innovative radiopharmaceutical now in advanced phase-three clinical trials. Positive completion of this phase will open the way to registration of the product by the Food and Drug Administration in the United States and the European Medicines Agency in the European Union.
The company plans a flexible model for market launch of the SYN2 cardiotracer, allowing for the possibility of its commercialization after completion of phase-three clinical trials, or, if justified by business considerations, during phase-three clinical trials, or after obtaining full registration.
Commercialization model
Syn2bio plans to implement a licensing and partnering model, which will enable SYN2 to be quickly and efficiently launched on major markets – in Europe, North America, and selected Asian countries – with limited capital and operational risk.
The natural partners for Syn2bio are global pharmaceutical groups, manufacturers of medical devices, and entities specializing in production of radiopharmaceuticals, with the necessary manufacturing and logistical infrastructure and network of contacts within the medical community.
On local markets, sublicences may be granted to entities with manufacturing plants meeting good manufacturing practice (GMP) standards, enabling rapid scaling of the availability of the product and adapting the distribution model to the specifics of individual countries.
A key element of Syn2bio’s strategy is maintaining and expanding patent protection – the foundation for the licensing value of SYN2 and the source of a competitive advantage on the nuclear medicine market.
Additional sources of recurring revenue
The company intends to retain the right to design and distribute disposable cassettes for synthesis of SYN2, used for production. This will ensure stable, recurring revenue regardless of the adopted licensing model or the scale of commercialization conducted by partners.
Syn2bio also plans to sell the chemical precursor necessary for attachment of the 18F isotope. This will enable not only the generation of additional revenue, but also maintaining control over the quality of the source material applied by licensees, ensuring compliance with GMP requirements, and conducting effective quality control procedures and audits.
Development of new projects
After completion of the process of commercialization of SYN2, the company plans to launch R&D work on further projects in the area of nuclear medicine – in particular the development of new radiopharmaceuticals.
The strategy calls for a concentration exclusively on diagnostic and therapeutic areas and health problems with high significance for the population, i.e. those affecting a large number of patients and of great importance for healthcare systems.